Health economic evaluation of a risk-stratified intervention in diabetic kidney disease
Authors' conclusion
We developed a robust model of DKD progression based on real-world data and demonstrated its value through economic modelling of risk-stratified interventions with known effectiveness. This model can aid policymakers and health professionals in evaluating population-level interventions for evidence-based policy decisions.
Study context
- Population
- Multi-ethnic Asian population with diabetes, Singapore Diabetic Cohort; validation in national administrative datasets (N=73,256)Singapore Diabetic Cohort
- Participants
- 9,660 participants
- Comparison
- Hypothetical SGLT2i intervention in low-risk vs high-risk individuals
- Outcome
- Annual DKD stage transitions
- Follow-up
- Annually
Methodological detailsmulti-state Markov model with cost-effectiveness and budget impact analysis, internally validated in 50% training and 50% testing datasets, externally validated in national administrative datasets, healthcare system perspective, hypothetical intervention
- Multi-state Markov model with cost-effectiveness and budget impact analysis
- Internally validated in 50% training and 50% testing datasets
- Externally validated in national administrative datasets
- Healthcare system perspective
- Hypothetical intervention
Main finding
As reported in the abstract
Participants staying in the same diabetic kidney disease (DKD) stage annually
53.0-88.8%
Further findings
Cost-effectiveness of SGLT2i intervention · short and long term
- Cost-effective in low-risk, but not in high-risk, individuals with T2D
Budget impact of SGLT2i intervention · 5 years
- 5 year cumulative cost increase, assuming annual 5% increase in market uptake
- 41.5%
Original publication
Health economic evaluation of a risk-stratified intervention in diabetic kidney disease. Diabetologia. Published 30 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →